CA2465247C - Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases - Google Patents
Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases Download PDFInfo
- Publication number
- CA2465247C CA2465247C CA2465247A CA2465247A CA2465247C CA 2465247 C CA2465247 C CA 2465247C CA 2465247 A CA2465247 A CA 2465247A CA 2465247 A CA2465247 A CA 2465247A CA 2465247 C CA2465247 C CA 2465247C
- Authority
- CA
- Canada
- Prior art keywords
- benzoimidazol
- pyrazol
- carboxylic acid
- dimethyl
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Abstract
L'invention concerne des composés physiologiquement actifs représentés par la formule générale (Ix), des compositions qui renferment ces composés, leurs promédicaments, des sels ou solvates de ces composés acceptables sur le plan pharmaceutique et leurs promédicaments, ainsi que de nouveaux médicaments entrant dans le champ d'application de la formule (Ix) et des procédés pour leur préparation. Ces composés et compositions possèdent des propriétés pharmaceutiques intéressantes, notamment la capacité d'inhiber les kinases.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0113868A FR2831537B1 (fr) | 2001-10-26 | 2001-10-26 | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation |
FR01/13868 | 2001-10-26 | ||
GB0206893A GB0206893D0 (en) | 2002-03-22 | 2002-03-22 | Chemical compounds |
GB0206895A GB0206895D0 (en) | 2002-03-22 | 2002-03-22 | Chemical compounds |
GB0206893.0 | 2002-03-22 | ||
GB0206895.5 | 2002-03-22 | ||
US39506002P | 2002-07-11 | 2002-07-11 | |
US39515102P | 2002-07-11 | 2002-07-11 | |
US60/395,060 | 2002-07-11 | ||
US60/395,151 | 2002-07-11 | ||
PCT/GB2002/004763 WO2003035065A1 (fr) | 2001-10-26 | 2002-10-24 | Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2465247A1 CA2465247A1 (fr) | 2003-05-01 |
CA2465247C true CA2465247C (fr) | 2010-05-18 |
Family
ID=27515325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2465247A Expired - Fee Related CA2465247C (fr) | 2001-10-26 | 2002-10-24 | Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1441725A1 (fr) |
JP (1) | JP5039268B2 (fr) |
AU (1) | AU2002334217B2 (fr) |
BR (1) | BR0213562A (fr) |
CA (1) | CA2465247C (fr) |
IL (1) | IL161576A0 (fr) |
MX (1) | MXPA04003954A (fr) |
UY (1) | UY27516A1 (fr) |
WO (1) | WO2003035065A1 (fr) |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2475633C (fr) * | 2002-02-06 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3 |
DE10227668A1 (de) * | 2002-06-20 | 2004-01-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arzneimittel zur Behandlung des systemic inflammatory response syndrome |
AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
US7309701B2 (en) | 2002-11-19 | 2007-12-18 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
US7462613B2 (en) | 2002-11-19 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
JP2004189738A (ja) * | 2002-11-29 | 2004-07-08 | Nippon Nohyaku Co Ltd | 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法 |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
GB0315657D0 (en) * | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
KR101190964B1 (ko) * | 2003-07-03 | 2012-10-12 | 아스텍스 테라퓨틱스 리미티드 | 벤즈이미다졸 유도체 및 단백질 키나제로서의 그의 용도 |
AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
RS51846B (en) * | 2003-09-08 | 2012-02-29 | Aventis Pharmaceuticals Inc. | TIENOPIRAZOLI |
AU2004283196B2 (en) * | 2003-09-17 | 2011-08-25 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
CA2548172A1 (fr) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines utiles comme inhibiteurs des proteines kinases |
WO2005065686A1 (fr) * | 2004-01-07 | 2005-07-21 | Adipogen Pharmaceuticals Pty Limited | Agents de modulation de la differenciation et utilisations associees |
WO2005079791A1 (fr) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Derives d'acide thiophene-2-carboxylique (1h-benzimidazol-2 yl)-amide et composes associes utilises comme inhibiteurs de la tec kinase itk (kinase des lymphocites inductibles par l'interleukine -2) pour traiter une inflammation et des troubles immunologiques et allergiques |
ITTO20040125A1 (it) * | 2004-03-01 | 2004-06-01 | Rotta Research Lab | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica |
DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
DE102004010194A1 (de) * | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln |
MX2007000791A (es) * | 2004-08-03 | 2007-03-23 | Wyeth Corp | Indazoles utiles en el tratamiento de enfermedades cardiovasculares. |
WO2006033943A2 (fr) | 2004-09-17 | 2006-03-30 | Exelixis, Inc | Modulateurs de kinases a base de pyrazole et leurs procedes d'utilisation |
TW200621232A (en) * | 2004-09-21 | 2006-07-01 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
CA2585925C (fr) * | 2004-10-27 | 2014-04-22 | Janssen Pharmaceutica, N.V. | Agents regulateurs de cannabinoides de type tetrahydropyridinylpyrazole |
WO2006066913A2 (fr) * | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques |
US7786113B2 (en) | 2004-12-23 | 2010-08-31 | Hoffman-La Roche Inc. | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
JP2008526723A (ja) * | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
KR20070108881A (ko) * | 2005-01-27 | 2007-11-13 | 교와 핫꼬 고교 가부시끼가이샤 | Igf-1r 저해제 |
DE602006002887D1 (de) * | 2005-04-14 | 2008-11-06 | Hoffmann La Roche | Tricyclische azolderivate, ihre herstellung und ihre verwendung als pharmazeutische mittel |
WO2006108489A1 (fr) * | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Derives aminopyrazole, leur fabrication et leur utilisation comme agents pharmaceutiques |
WO2006134318A1 (fr) * | 2005-06-11 | 2006-12-21 | Vernalis R & D Limited | Dérivés de benzimidazole substitués au pyrazole pour une utilisation dans le traitement du cancer et de troubles auto-immuns |
WO2007001939A1 (fr) * | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Composes tetrahydro-pyranopyrazole presentant des activites de modulation de cannabinoïde |
TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
WO2007017143A1 (fr) * | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux |
EP1912987A1 (fr) | 2005-08-01 | 2008-04-23 | F. Hoffmann-Roche AG | Derives benzylamino heterocycliques, leurs procedes de fabrication et leur utilisation en tant qu'agents pharmaceutiques |
BRPI0619955A2 (pt) * | 2005-12-15 | 2011-10-25 | Hoffmann La Roche | derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos |
EP1968579A1 (fr) * | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Composes pharmaceutiques |
CA2637392A1 (fr) * | 2006-01-23 | 2007-07-26 | Crystalgenomics, Inc. | Derives d'imidazopyridine inhibant l'activite de la proteine kinase, methode de preparation de ces derniers et composition pharmaceutique les comprenant |
NZ571705A (en) * | 2006-04-14 | 2012-03-30 | Abbott Lab | Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors |
WO2008001115A2 (fr) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
FR2903406B1 (fr) * | 2006-07-04 | 2012-08-10 | Aventis Pharma Sa | Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
US8642598B2 (en) | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
DE102006060598A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
RU2501803C2 (ru) | 2007-10-01 | 2013-12-20 | Айзис Фармасьютикалз, Инк. | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) |
GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2294065B1 (fr) | 2008-01-22 | 2014-03-19 | Vernalis (R&D) Ltd. | Dérivés d'indolyl-pyridone comme inhibiteurs de la checkpoint-kinase-1 |
GB0803018D0 (en) * | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
WO2009138799A1 (fr) * | 2008-05-14 | 2009-11-19 | Astex Therapeutics Limited | Utilisation thérapeutique de la 1-cyclopropyl-3-[3-(5-morpholin-4-ylméthyl-1h-benzoimidazol-2-yl)-lh-pyrazol-4-yl]-urée |
US8148363B2 (en) * | 2008-05-19 | 2012-04-03 | Schering Corporation | Heterocyclic compounds as factor IXA inhibitors |
CN104193740A (zh) * | 2008-07-03 | 2014-12-10 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 |
GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
AR074776A1 (es) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
CN101619058A (zh) * | 2009-01-08 | 2010-01-06 | 上海交通大学 | 一种苯并咪唑-4-酰胺型衍生物 |
MX2012000435A (es) | 2009-07-08 | 2012-06-01 | Dermira Canada Inc | Analogos de acido 5-(tetradeciloxi)-2-furancarboxilico (tofa) utiles en el tratamiento de trastornos o afecciones dermatologicas. |
BR112012008094A2 (pt) | 2009-08-07 | 2020-08-18 | Chugai Seiyaku Kabushiki Kaisha | derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer |
EP2464231A4 (fr) * | 2009-08-10 | 2013-02-06 | Samumed Llc | Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/bêta-caténine et utilisations thérapeutiques de ceux-ci |
BR112012002854B1 (pt) | 2009-08-10 | 2020-02-18 | Samumed, Llc | Composto ou sal farmaceuticamente aceitável, composição farmacêutica e uso dos mesmos |
US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
US8710245B2 (en) | 2009-12-04 | 2014-04-29 | Psychogenics Inc. | Multicyclic compounds and methods of use thereof |
PL3001903T3 (pl) | 2009-12-21 | 2018-03-30 | Samumed, Llc | 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
JP5845502B2 (ja) | 2010-06-01 | 2016-01-20 | サミット セラピューティクス ピーエルシー | クロストリジウム・ディフィシル関連疾患を治療するための化合物 |
GB2482501A (en) * | 2010-08-04 | 2012-02-08 | Summit Corp Plc | Novel compounds for use in the treatment of Clostridium Difficile and associated diseases |
WO2012020725A1 (fr) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5 |
CN102372674A (zh) * | 2010-08-17 | 2012-03-14 | 上海药明康德新药开发有限公司 | 医药中间体3-醛基-4-卤代吡唑的合成方法 |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
CA2810954A1 (fr) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Composes heterocycliques et leur utilisation en tant qu'inhibiteurs de la glycogene synthase kinase-3 |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
BR112013025142A2 (pt) | 2011-04-01 | 2019-09-24 | Univ Utah Res Found | análogos de 3-(1h-benzo{d}imidazol-2-il)-1h-indazol substituído como inibidores da cinase pdk1 |
CN103597074A (zh) | 2011-06-16 | 2014-02-19 | Isis制药公司 | 成纤维细胞生长因子受体4表达的反义调节 |
DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
CN103929963A (zh) | 2011-09-14 | 2014-07-16 | 萨穆梅德有限公司 | 吲唑-3-羧酰胺及其作为WNT/β-CATENIN信号传导通路抑制剂的用途 |
US9351973B2 (en) | 2011-09-22 | 2016-05-31 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
CA2849566C (fr) | 2011-11-09 | 2021-02-09 | Cancer Research Technology Limited | Composes de type 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile et leur utilisation therapeutique |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
MA37577B1 (fr) | 2012-05-04 | 2018-05-31 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
EP2855448B1 (fr) | 2012-05-15 | 2017-02-08 | Cancer Research Technology Ltd | 5-[[4-[[morpholin-2-yl]méthylamino]-5-(trifluorométhyl)-2-pyridyl]- amino]pyrazine-2-carbonitrile et utilisations thérapeutiques de celui-ci |
EP2857396B1 (fr) * | 2012-05-31 | 2018-11-21 | Sumitomo Chemical Co., Ltd | Composés hétérocycliques condensés pour la lutte contre les nuisibles |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
RU2015117950A (ru) * | 2012-10-26 | 2016-12-20 | Ф. Хоффманн-Ля Рош Аг | 3,4-дизамещенный 1н-пиразол и 4,5-дизамещенный тиазол в качестве ингибиторов тирозинкиназы syk |
JP6355648B2 (ja) | 2013-01-08 | 2018-07-11 | サミュメッド リミテッド ライアビリティ カンパニー | Wntシグナル伝達経路の3−(ベンゾイミダゾール−2−イル)−インダゾール阻害剤およびそれらの治療的使用 |
GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ampkを活性化させるインダゾール化合物 |
JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
CN104447701B (zh) * | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
WO2015099127A1 (fr) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Gène mutant de fgfr gardien et médicament ciblant celui-ci |
CN104098513B (zh) * | 2014-07-30 | 2016-08-24 | 天津市斯芬克司药物研发有限公司 | 一种吲唑化合物衍生物及其制备方法 |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
EP3189041B1 (fr) | 2014-09-03 | 2021-04-28 | Ctxt Pty Ltd | Derives de la tetrahydroisoquinoline en tant qu'inhibiteurs de la prmt5 |
US10005792B2 (en) | 2014-09-03 | 2018-06-26 | Ctxt Pty. Ltd. | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors |
WO2016040190A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques |
WO2016040193A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques |
WO2016040185A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques |
WO2016040181A1 (fr) * | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040180A1 (fr) * | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040188A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040182A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques |
WO2016040184A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
AU2015373996B2 (en) * | 2014-12-30 | 2020-10-08 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
CN107849015B (zh) * | 2015-05-21 | 2021-03-19 | 葛兰素知识产权发展有限公司 | 作为pad4抑制剂的苯并咪唑衍生物 |
US10479780B2 (en) | 2015-06-17 | 2019-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives |
WO2016202758A1 (fr) * | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués |
WO2017024025A1 (fr) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024003A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023972A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
WO2017024010A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques |
WO2017023987A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
WO2017023984A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques |
US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023993A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
KR20180080262A (ko) | 2015-11-06 | 2018-07-11 | 사뮤메드, 엘엘씨 | 골관절염의 치료 |
MA43169B1 (fr) | 2015-11-06 | 2022-05-31 | Incyte Corp | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma |
AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
WO2017120194A1 (fr) | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine et utilisation de composés de la pyridimine comme inhibiteurs de pi3k-gamma |
GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
ES2933109T3 (es) | 2016-06-01 | 2023-02-02 | Biosplice Therapeutics Inc | Proceso para preparar N-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida |
AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
EP3490607A4 (fr) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | Composés et compositions, et utilisations associées |
CN116514761A (zh) | 2016-07-29 | 2023-08-01 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
WO2018075858A1 (fr) | 2016-10-21 | 2018-04-26 | Samumed, Llc | PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE |
EP3534878A1 (fr) | 2016-11-07 | 2019-09-11 | Samumed, LLC | Formulations injectables à dose unique prêtes à l'emploi |
WO2018125799A2 (fr) | 2016-12-29 | 2018-07-05 | Viamet Pharmaceuticals (Bermuda), Ltd. | Composés inhibiteurs des métalloenzymes |
DK3562487T3 (da) | 2016-12-29 | 2024-01-02 | Ji Xing Pharmaceuticals Hong Kong Ltd | Metalloenzyminhibitorforbindelser |
CA3053903A1 (fr) | 2017-02-16 | 2018-08-23 | Sunovion Pharmaceuticals Inc. | Procedes de traitement de la schizophrenie |
SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
LT3697789T (lt) | 2017-10-18 | 2021-12-10 | Incyte Corporation | Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai |
MX2020008537A (es) | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Sales, formas cristalinas y metodos de produccion de las mismas. |
CN108546266B (zh) * | 2018-07-25 | 2020-09-22 | 上海毕得医药科技有限公司 | 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法 |
CA3103995A1 (fr) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci |
MA53561A (fr) | 2018-09-05 | 2022-05-11 | Incyte Corp | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
MX2021007925A (es) | 2018-12-31 | 2021-10-26 | Biomea Fusion Llc | Inhibidores irreversibles de la interaccion menina-mll. |
EP3911317A2 (fr) * | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk |
KR20210139376A (ko) | 2019-03-14 | 2021-11-22 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물 |
WO2021060307A1 (fr) * | 2019-09-25 | 2021-04-01 | 富士フイルム株式会社 | Composé imidazopyridine ou sel de celui-ci, et composition pharmaceutique |
EP4077316A1 (fr) * | 2019-12-20 | 2022-10-26 | Pfizer Inc. | Dérivés de benzimidazole |
KR20230003503A (ko) | 2020-04-14 | 2023-01-06 | 선오비온 파마슈티컬스 인코포레이티드 | 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민 |
CN112239452B (zh) * | 2020-10-14 | 2022-05-10 | 武汉尚赛光电科技有限公司 | 一种电子传输型杂蒽衍生物及其有机电致发光器件 |
CN114478511B (zh) * | 2022-02-24 | 2023-06-20 | 中国药科大学 | 苯并恶唑类化合物及其制备方法、药物组合物和应用 |
WO2023234970A1 (fr) * | 2022-06-01 | 2023-12-07 | KUDA Therapeutics, Inc. | Dérivés d'imidazopyridine et d'oxazolopyridine et leurs analogues, leurs procédés de préparation, procédés d'inhibition de la voie hif-1/2a et induction de la ferroptose |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2130029A1 (de) * | 1971-06-18 | 1972-12-21 | Bayer Ag | Verfahren zur Herstellung von 2-[Pyrazolyl-(1)]-benzimidazolen |
DE2130030A1 (de) * | 1971-06-18 | 1972-12-21 | Bayer Ag | Fungizide und bakterizide Mittel |
BE793501A (fr) * | 1971-12-31 | 1973-06-29 | Ciba Geigy | Composes heterocycliques et produits phytopharmaceutiques qui en contiennent |
CA2203517A1 (fr) * | 1994-11-10 | 1996-05-23 | Alan M. Laibelman | Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases |
ATE231504T1 (de) * | 1997-04-11 | 2003-02-15 | Grelan Pharmaceutical Co | Pyrazolderivate und sie enthaltende cox- inhibitoren |
ATE301651T1 (de) * | 1999-06-23 | 2005-08-15 | Aventis Pharma Gmbh | Substituierte benzimidazole |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
-
2002
- 2002-10-24 JP JP2003537632A patent/JP5039268B2/ja not_active Expired - Fee Related
- 2002-10-24 MX MXPA04003954A patent/MXPA04003954A/es active IP Right Grant
- 2002-10-24 BR BR0213562-0A patent/BR0213562A/pt not_active Application Discontinuation
- 2002-10-24 WO PCT/GB2002/004763 patent/WO2003035065A1/fr active Application Filing
- 2002-10-24 IL IL16157602A patent/IL161576A0/xx unknown
- 2002-10-24 AU AU2002334217A patent/AU2002334217B2/en not_active Ceased
- 2002-10-24 CA CA2465247A patent/CA2465247C/fr not_active Expired - Fee Related
- 2002-10-24 EP EP02801954A patent/EP1441725A1/fr not_active Withdrawn
- 2002-10-25 UY UY27516A patent/UY27516A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL161576A0 (en) | 2004-09-27 |
BR0213562A (pt) | 2004-08-31 |
JP2005509633A (ja) | 2005-04-14 |
EP1441725A1 (fr) | 2004-08-04 |
CA2465247A1 (fr) | 2003-05-01 |
MXPA04003954A (es) | 2004-11-29 |
WO2003035065A1 (fr) | 2003-05-01 |
AU2002334217B2 (en) | 2008-07-03 |
JP5039268B2 (ja) | 2012-10-03 |
UY27516A1 (es) | 2003-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2465247C (fr) | Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases | |
US6897208B2 (en) | Benzimidazoles | |
AU2002334217A1 (en) | Benzimidazoles and analogues and their use as protein kinases inhibitors | |
US10995078B2 (en) | Compounds and compositions for inhibition of FASN | |
CA2451678C (fr) | Azaindoles | |
CA2395593C (fr) | Azaindoles | |
AU2004253338B2 (en) | Benzimidazole derivatives and their use as protein kinases inhibitors | |
JP4377228B2 (ja) | ベンゾイミダゾール誘導体、およびkdrキナーゼタンパク質阻害剤としてのその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20141024 |